rt-PA for ischaemic stroke: what will the next question be?

Affiliations

Comment

Didier Leys et al. Lancet. 2012.

. 2012 Jun 23;379(9834):2320-1.

doi: 10.1016/S0140-6736(12)60822-8. Epub 2012 May 23.

¹ Department of Neurology, Stroke Unit, Roger Salengro Hospital, F-59037 Lille, France. didier.leys@chru-lille.fr

No abstract available

Comment on

Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis.
Wardlaw JM, Murray V, Berge E, del Zoppo G, Sandercock P, Lindley RL, Cohen G. Wardlaw JM, et al. Lancet. 2012 Jun 23;379(9834):2364-72. doi: 10.1016/S0140-6736(12)60738-7. Epub 2012 May 23. Lancet. 2012. PMID: 22632907 Free PMC article.
The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.
IST-3 collaborative group; Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, Murray G, Innes K, Venables G, Czlonkowska A, Kobayashi A, Ricci S, Murray V, Berge E, Slot KB, Hankey GJ, Correia M, Peeters A, Matz K, Lyrer P, Gubitz G, Phillips SJ, Arauz A. IST-3 collaborative group, et al. Lancet. 2012 Jun 23;379(9834):2352-63. doi: 10.1016/S0140-6736(12)60768-5. Epub 2012 May 23. Lancet. 2012. PMID: 22632908 Free PMC article. Clinical Trial.